These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

465 related articles for article (PubMed ID: 30376740)

  • 1. An update: emerging drugs to treat squamous cell carcinomas of the head and neck.
    Lee YS; Johnson DE; Grandis JR
    Expert Opin Emerg Drugs; 2018 Dec; 23(4):283-299. PubMed ID: 30376740
    [No Abstract]   [Full Text] [Related]  

  • 2. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC).
    Cohen EEW; Bell RB; Bifulco CB; Burtness B; Gillison ML; Harrington KJ; Le QT; Lee NY; Leidner R; Lewis RL; Licitra L; Mehanna H; Mell LK; Raben A; Sikora AG; Uppaluri R; Whitworth F; Zandberg DP; Ferris RL
    J Immunother Cancer; 2019 Jul; 7(1):184. PubMed ID: 31307547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients.
    Li L; Chen L; Yan L; Guo Y; Li F; Fan M; Lan M; Lai X; Zhou J; Huang Y; Xu P; Lang J; Feng M
    Radiat Oncol; 2023 Jul; 18(1):109. PubMed ID: 37403098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging immune checkpoint inhibitors for the treatment of head and neck cancers.
    Green SE; McCusker MG; Mehra R
    Expert Opin Emerg Drugs; 2020 Dec; 25(4):501-514. PubMed ID: 33196319
    [No Abstract]   [Full Text] [Related]  

  • 5. Treating Head and Neck Cancer in the Age of Immunotherapy: A 2023 Update.
    Bhatia A; Burtness B
    Drugs; 2023 Feb; 83(3):217-248. PubMed ID: 36645621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapies and Future Combination Strategies for Head and Neck Squamous Cell Carcinoma.
    Cristina V; Herrera-Gómez RG; Szturz P; Espeli V; Siano M
    Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31671550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC).
    Cohen RB
    Cancer Treat Rev; 2014 May; 40(4):567-77. PubMed ID: 24216225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted Therapy in Head and Neck Cancer: An Update on Current Clinical Developments in Epidermal Growth Factor Receptor-Targeted Therapy and Immunotherapies.
    Moreira J; Tobias A; O'Brien MP; Agulnik M
    Drugs; 2017 May; 77(8):843-857. PubMed ID: 28382569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging drugs for head and neck cancer.
    Wen Y; Grandis JR
    Expert Opin Emerg Drugs; 2015 Jun; 20(2):313-29. PubMed ID: 25826749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging tyrosine kinase inhibitors for head and neck cancer.
    Long Z; Grandis JR; Johnson DE
    Expert Opin Emerg Drugs; 2022 Sep; 27(3):333-344. PubMed ID: 36131561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protocol for the EACH trial: a multicentre phase II study evaluating the safety and antitumour activity of the combination of avelumab, an anti-PD-L1 agent, and cetuximab, as any line treatment for patients with recurrent/metastatic head and neck squamous cell cancer (HNSCC) in the UK.
    Ng K; Metcalf R; Sacco J; Kong A; Wheeler G; Forsyth S; Bhat R; Ward J; Ensell L; Lowe H; Spanswick V; Hartley J; White L; Lloyd-Dehler E; Forster M
    BMJ Open; 2023 Nov; 13(11):e070391. PubMed ID: 38011968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing treatments for recurrent or metastatic head and neck squamous cell carcinoma.
    Specenier P; Vermorken JB
    Expert Rev Anticancer Ther; 2018 Sep; 18(9):901-915. PubMed ID: 29999437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials.
    Poulose JV; Kainickal CT
    World J Clin Oncol; 2022 May; 13(5):388-411. PubMed ID: 35662989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of anti-EGFR agents administered concurrently with standard therapies for patients with head and neck squamous cell carcinoma: a systematic review and meta-analysis of randomized controlled trials.
    Tian Y; Lin J; Tian Y; Zhang G; Zeng X; Zheng R; Zhang W; Yuan Y
    Int J Cancer; 2018 Jun; 142(11):2198-2206. PubMed ID: 29143328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancing programmed cell death protein 1 axis inhibition in head and neck squamous cell carcinoma: Combination immunotherapy.
    Vathiotis IA; Johnson JM; Argiris A
    Cancer Treat Rev; 2021 Jun; 97():102192. PubMed ID: 33819755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigational multitargeted kinase inhibitors in development for head and neck neoplasms.
    Sola AM; Johnson DE; Grandis JR
    Expert Opin Investig Drugs; 2019 Apr; 28(4):351-363. PubMed ID: 30753792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current Prospects of Molecular Therapeutics in Head and Neck Squamous Cell Carcinoma.
    Devaraja K
    Pharmaceut Med; 2019 Aug; 33(4):269-289. PubMed ID: 31933185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent insights in the PI3K/Akt pathway as a promising therapeutic target in combination with EGFR-targeting agents to treat head and neck squamous cell carcinoma.
    Zaryouh H; De Pauw I; Baysal H; Peeters M; Vermorken JB; Lardon F; Wouters A
    Med Res Rev; 2022 Jan; 42(1):112-155. PubMed ID: 33928670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of epidermal growth factor receptor inhibitor-induced interferon pathway signaling in the head and neck squamous cell carcinoma therapeutic response.
    Korpela SP; Hinz TK; Oweida A; Kim J; Calhoun J; Ferris R; Nemenoff RA; Karam SD; Clambey ET; Heasley LE
    J Transl Med; 2021 Jan; 19(1):43. PubMed ID: 33485341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy in Patients with Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck.
    Łasińska I; Kolenda T; Teresiak A; Lamperska KM; Galus Ł; Mackiewicz J
    Anticancer Agents Med Chem; 2019; 19(3):290-303. PubMed ID: 30198439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.